Pulnovo Medical Announces Results of the PADN-HF-PH Trial at ESC Congress 2026, Simultaneously Published in The New England Journal of Medicine (NEJM)
Data ReadoutpositivePulmonary (incomplete name in source)Positive
AI Analysis
Summary
Pulnovo Medical announced positive Phase 3 PADN-HF-PH trial results in 264 PH-LHD patients showing 51% reduction in clinical worsening risk and 35.5% decrease in recurrent events, with results simultaneously published in NEJM and presented at ESC Congress 2026.
Clinical Trial Data
Primary Endpoint
Met
Patients
264
Outcome Details
51% reduction in risk of clinical worsening, 35.5% decrease in recurrent clinical events, sustained improvements in functional capacity
Importance:8/10
Sentiment:
0.85
Phase 3Data ReadoutNEJM PublicationESC Congress 2026Pulmonary HypertensionClinical Trial Results
Read the original article
Published by PR Newswire Pharma on September 3, 2026 11:53 AM